{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"groups":[{"description":"One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.","id":"OG000","title":"Not Assigned"},{"description":"Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG001","title":"COB 20 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG002","title":"COB 40 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG003","title":"COB 80 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.","id":"OG004","title":"COB 80 mg + GDC 400 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG005","title":"COB 100 mg + GDC 200 mg"}],"populationDescription":"Data for this measure were not collected.","reportingStatus":"POSTED","timeFrame":"Up to day 22 of study","title":"Mean Terminal Half-life (t1/2)","type":"SECONDARY"}